Atopic Dermatitis

Raj Chovatiya, MD, PhD, and Adelaide A. Hebert, MD, FAAD, discuss the current treatment landscape of atopic dermatitis (AD), as well as key factors when selecting treatment for patients with the disease.

Biolojic’s BD9 is a dual specific antibody that can block both Thymic stromal lymphopoietin and IL-13.

At the 2023 RAD Virtual Conference, Chovatiya presented a session titled, "Living the Cream."

The poster was presented at the 2023 Revolutionizing Atopic Dermatitis (RAD) Virtual Conference.

Dr Lal, an expert in dermatology, presents the case of a 45-year-old female with a history of childhood AD marked by severe symptoms. He recaps a panel conversation on the approach to treatment, emphasizing the importance of initiating effective and long-lasting treatment options for optimal relief.

Karan Lal, DO, MS, FAAD, discusses a case involving a 4-year-old male with atopic dermatitis, covering FDA-approved treatments for this age group, strategies for tapering and stopping treatment, the impact of the atopic march, and challenges with treatment prior authorizations.

Christopher Bunick, MD, PhD, presented the research during a late-breaking research session during the 2023 Revolutionizing Atopic Dermatitis Virtual Conference.

From the December cover feature: Christopher Bunick, MD, PhD; Aaron Drucker, MD, ScM; and Mona Shahriari, MD, share their thoughts on AAD’s updated atopic dermatitis guidelines.

Jennifer Etienne shared her experiences during the shared decision-making patient panel of the 2023 Revolutionizing Atopic Dermatitis Virtual Conference.

A poster from the 2023 Revolutionizing Atopic Dermatitis Conference revealed a link between AD, impaired oral health, and oral dysbiosis.

Alan Irvine, MD, DSc, discusses his Revolutionizing Atopic Dermatitis session and exciting advances in AD.

Approximately 76% of patients reported being "satisfied," while 18% reported they were "very satisfied" with treatment.

KT-474 is a first-in-class, investigational IRAK4 degrader.

An expert in the management of skin conditions provides an overview of a 20-year-old male diagnosed with atopic dermatitis, discussing key insights from a round table discussion. The conversation focused on effective management strategies, best practices for prior authorization approvals, and the significance of treatment vehicles.

Monica Harilall, PA-C, MMS, delves into the case of an 18-year-old female with atopic dermatitis, highlighting the challenges in managing adolescent patients who are self-conscious about their condition and seek rapid results. The discussion explores effective ways to communicate treatment mechanisms to patients and engage them collaboratively in the treatment selection process.

Zakiya Pressley Rice, MD, took a deep dive into how atopic dermatitis severity and increased rates of grade school absenteeism affect patients with skin of color during a recent Masterclasses in Dermatology meeting.

Understanding these relationships is crucial for developing effective clinical management strategies for patients with AD, according to a recent literature review.

The sNDA is supported by positive data from the phase 3 INTEGUMENT-1 and INTEGUMENT-2 trials.

A phase 1 study found that RPT193 monotherapy led to greater improvements in clinical efficacy than treatment with a placebo.

Ted Lain, MD, MBA, moderated a discussion to share strategies to optimize treatment sequencing, reevaluate long-term management, understand barriers to novel therapies, promote prior authorization integration, and diversify treatment areas.

Audrey Dean’s case highlights the significance of tailoring treatments to individual patient needs, acknowledging that what works for one person might not work for another.

Connect Biopharma announced positive long-term data from its China pivotal trial.

Patients with AD and a comorbid allergic condition achieved the same efficacy endpoints as patients without allergic conditions in a study.

From the November cover: Raj Chovatiya, MD, PhD, and Lawrence Eichenfield, MD, shared their insights and key treatment pearls into atopic dermatitis management for adults and children.

Jared Gollob, MD, Chief Medical Officer of Kymera Therapeutics, spoke with Dermatology Times to discuss these trial results.

Germany will be the first country where lebrikizumab will be available for prescription, with a subsequent rollout across European countries throughout 2024.

What are some of the challenges and triumphs in using biologics for atopic dermatitis? Abby L. Allen, RN, NP, shares insights at the American College of Allergy, Asthma and Immunology 2023 Annual Scientific Meeting.

Research at the American College of Allergy, Asthma and Immunology (ACAAI) 2023 Annual Scientific Meeting discusses the impact of an educational program on improving care.

Ruchi Gupta, MD, MPH, shares tips for supporting a successful transition to college for patients with atopic dermatitis.

A new study presented at this year’s American College of Allergy, Asthma and Immunology Annual Scientific Meeting highlights the need for mental health support in patients with atopic dermatitis.